Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) had its price objective reduced by equities researchers at Canaccord Genuity Group from $153.00 to $149.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Canaccord Genuity Group‘s price target would suggest a potential upside of 308.22% from the company’s current price.
Other equities research analysts also recently issued research reports about the company. Leerink Partners began coverage on Nektar Therapeutics in a research report on Monday, October 12th. They set an “outperform” rating and a $130.00 price target for the company. Wedbush cut their price objective on Nektar Therapeutics from $80.00 to $50.00 and set a “neutral” rating on the stock in a report on Wednesday, September 23rd. JPMorgan Chase & Co. started coverage on Nektar Therapeutics in a research note on Friday, August 21st. They issued a “neutral” rating and a $65.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nektar Therapeutics in a report on Friday, August 28th. Finally, UBS Group started coverage on Nektar Therapeutics in a report on Monday, October 12th. They set a “neutral” rating and a $53.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Nektar Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $130.33.
Check Out Our Latest Research Report on NKTR
Nektar Therapeutics Trading Down 2.1%
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The biopharmaceutical company reported ($1.63) EPS for the quarter, topping analysts’ consensus estimates of ($2.07) by $0.44. The business had revenue of $9.39 million during the quarter, compared to the consensus estimate of $10.27 million. Nektar Therapeutics had a negative return on equity of 29.31% and a negative net margin of 339.67%. As a group, equities analysts predict that Nektar Therapeutics will post -8.08 EPS for the current fiscal year.
Insider Transactions at Nektar Therapeutics
In related news, CEO Howard Robin sold 418 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $71.98, for a total value of $30,087.64. Following the completion of the sale, the chief executive officer directly owned 54,627 shares in the company, valued at approximately $3,932,051.46. This represents a 0.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 2.50% of the company’s stock.
Institutional Investors Weigh In On Nektar Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of the stock. Orbimed Advisors LLC purchased a new stake in shares of Nektar Therapeutics during the 1st quarter valued at about $19,786,000. Two Seas Capital LP lifted its position in shares of Nektar Therapeutics by 8.2% during the third quarter. Two Seas Capital LP now owns 3,345,978 shares of the biopharmaceutical company’s stock worth $202,582,000 after purchasing an additional 253,744 shares in the last quarter. Braidwell LP lifted its position in shares of Nektar Therapeutics by 112.7% during the second quarter. Braidwell LP now owns 473,617 shares of the biopharmaceutical company’s stock worth $33,063,000 after purchasing an additional 250,916 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Nektar Therapeutics during the second quarter worth $6,706,000. Finally, ACT Capital Partners L.P. purchased a new position in shares of Nektar Therapeutics in the third quarter valued at $5,473,000. Hedge funds and other institutional investors own 75.88% of the company’s stock.
Nektar Therapeutics Company Profile
Nektar Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco, California. It discovers and develops medicines, with a current focus on treatments for autoimmune and inflammatory diseases. Its lead investigational program, rezpegaldesleukin (REZPEG), is designed to stimulate regulatory T cells, which help regulate immune responses. Nektar is studying the candidate in clinical trials for immune-mediated conditions; it is not an approved medicine. Founded in 1990 as Inhale Therapeutic Systems, the company later adopted the Nektar name as it expanded its drug-development work.
Recommended Stories
- Five stocks we like better than Nektar Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
